Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

Submitted by admin on October 30, 2023 - 10:23am

Source:

Reuters

News Tags:

Bluebird Bio

priority review vouchers

sickle cell disease

gene therapy

Headline:

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

snippet:

Bluebird bio (BLUE.O) said on Monday it has agreed to sell its priority review voucher for $103 million if it gets the U.S. Food and Drug Administration's approval for its gene therapy to treat sickle cell disease.

Search form

You are here

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved